Intracranial Pressure Monitoring Fails to Help Traumatic Brain Injury Patients: Study

|

Monitoring for intracranial pressure following a head trauma appears to provide little, if any, benefits to patients who have suffered a traumatic brain injury (TBI), and in some cases may have worsened their condition, according to the findings of a new study.

In findings published on September 27 in the medical journal JAMA Network Open, researchers indicate critically ill brain injury patients who received intracranial pressure (ICP) monitoring undergo more medical and surgical intervention than patients who were not monitored, and were actually more likely to suffer respiratory complications, infections, and other health problems.

Traumatic brain injuries can occur from a forceful blow to the head, or an object that pierces the skull. The injuries can disrupt normal brain function, cause permanent disability, and may result in death.

Patients who suffer severe TBI commonly experience elevated intracranial pressure, and the growing pressure inside of the skull can lead to uncontrolled intracranial hypertension. This can result in life-threatening consequences if the condition is not treated, can shift the brain’s structure, block blood supply to the brain or compress the brain stem, which can lead to hemorrhaging and a stroke.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

Intracranial Pressure Monitoring for Traumatic Brain Injuries

Prior studies have suggested that critically ill TBI patients may benefit from ICP monitoring devices, which are placed inside of the head and monitor skull pressure to detect and treat intracranial hypertension.

In this latest study, Italian researchers analyzed data on 1,448 patients admitted to intensive care units with a TBI in Italy and Hungary, of which 503 patients received intracranial pressure monitoring, and 945 patients did not.

While mortality rates were similar in both monitored and unmonitored TBI patients, monitored patients were found to suffer higher rates of moderate and severe disability, respiratory and infectious complications, required more treatments and longer periods of mechanical ventilation or hospitalization, and had lower rates of good recovery outcomes than unmonitored patients did after a period of six months.

The researchers suggested that the poorer outcomes of monitored TBI patients could be the result of adverse side effects from the increased medical interventions. Those interventions may have been spurred by the increased monitoring. However, researchers indicate that intracranial pressure monitoring requires further investigation and observational studies to improve TBI patient recovery outcomes.

“This study found a significant association between ICP monitoring and worse patient outcomes, which could be explained by the increased use of medical therapies, with their significant adverse effects, among monitored patients,” the researchers concluded. “This result does not question the value of knowing the ICP values but how they should be used to improve patient outcome.”


0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

Breast mesh implants promoted as internal bras are now under scrutiny, following studies and FDA warnings linking the devices to infections, implant loss, and surgical failure. Lawsuits are being investigated for women who suffered complications after reconstruction or augmentation procedures involving products like GalaFLEX, Phasix, Strattice, and AlloDerm.
Dupixent users are coming forward with accounts of devastating cancer diagnoses, saying the popular eczema drug masked early warning signs of cutaneous T-cell lymphoma. As the FDA investigates and the first lawsuit is filed, researchers warn Dupixent may unmask or accelerate hidden cancers, raising urgent questions about its long-term safety.
Plaintiffs involved in GLP-1 vision loss lawsuits are calling for the litigation to be consolidated in New Jersey federal court, and not be bundled with existing stomach paralysis litigation.